electroCore Secures Two U.S. Patents, Extends IP Protection to 2039
electroCore secured U.S. Patent Nos. 12,208,263 and 12,213,795 for non-invasive vagus nerve stimulation methods and remote therapy monitoring. These filings grow its U.S. patent estate past 160 grants with terms extending protection to at least 2039, reinforcing barriers to competition in migraine and wellness therapies.
1. Patent Issuance Details
On January 28 and February 4, 2026 electroCore received U.S. Patent Nos. 12,208,263 and 12,213,795 covering methods for vagus nerve modulation via conductive gel electrodes and systems for remote therapy monitoring with data optimization. These grants protect core gammaCore and remote patient-monitoring technologies.
2. Portfolio Expansion
These two additions bring the company’s U.S. patent count above 160 grants, supported by numerous pending applications in the U.S. and internationally. Combined with existing patents on device design, stimulation waveforms, treatment methods and patient interfaces, the portfolio’s term is potentially extended through at least 2039.
3. Competitive Implications
The enlarged IP estate establishes multiple layers of exclusivity across migraine, cluster headache and wellness indications, creating substantial barriers to entry. Extended protection and comprehensive coverage of both core nVNS platforms and remote-monitoring capabilities position electroCore to defend market share and support long-term growth.